Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Attralus
AddedFeb 15, 2024
UpdatedJun 18, 2026
Attralus

Attralus

Series B

Attralus: A biopharmaceutical firm innovating transformative medicines for all stages of systemic amyloidosis.

HQ
San Francisco, CA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Attralus, founded with a mission to transform the treatment landscape for systemic amyloidosis, is a biopharmaceutical company dedicated to developing innovative medicines. The company focuses on creating peptide-based pan-amyloid targeting agents that can diagnose and treat all forms and stages of systemic amyloidosis. By addressing the common pathology across all subtypes of the disease, Attralus aims to provide comprehensive treatment options for patients suffering from this debilitating condition.

Notable figures associated with Attralus include leading experts in biopharmaceuticals and systemic amyloidosis research. The company has attracted significant investment from prominent venture capital firms, underscoring its potential impact in the medical field. Key achievements include the development of novel pan-amyloid removal (PAR) therapeutics, which have shown promise in binding to and removing toxic amyloid deposits. This breakthrough positions Attralus as a pivotal player in addressing unmet medical needs and improving patient outcomes in systemic amyloidosis.

Attralus - Similar Companies

AltPep logo

AltPep

altpep.com

Aurion Biotech logo

Aurion Biotech

aurionbiotech.com

Adrx logo

Adrx

adrxpharma.com

Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

amylyx.com

Alltrna logo

Alltrna

alltrna.com

Astria Therapeutics logo

Astria Therapeutics

astriatx.com

Amplifica logo

Amplifica

amplificabio.com

Ampersand Biomedicines logo

Ampersand Biomedicines

ampersand.bio

Attune Pharmaceuticals logo

Attune Pharmaceuticals

Atavistik Bio logo

Atavistik Bio

atavistikbio.com

Underdog Pharmaceuticals logo

Underdog Pharmaceuticals

cyclaritytx.com

Curie.Bio logo

Curie.Bio

curie.bio

Repair Biotechnologies logo

Repair Biotechnologies

Altos Labs logo

Altos Labs

altoslabs.com

ALT Bioscience logo

ALT Bioscience

Attralus - Quick Facts

Who are Attralus' competitors?

Companies similar to Attralus include AltPep, Aurion Biotech, Adrx and Amylyx Pharmaceuticals.

When was Attralus founded?

Attralus was founded in 2019.

Where is Attralus' headquarters located?

Attralus' headquarters is located in San Francisco, CA, US.

When was Attralus' last funding round?

Attralus' most recent funding round was for $116M (USD) in September 2021.

How much has Attralus raised to-date?

As of Sep 8, 2021, Attralus has raised a total of $141.2M (USD).

How many employees does Attralus have?

Attralus has 29 employees as of Feb 5, 2024.

Attralus - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Biopharmaceuticals
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified